Viatris completed the acquisition of a 5.1% stake in Syngene from Biocon for $153m.

Viatris, a global pharmaceutical company, completed the acquisition of a 5.1% stake in Syngene, an innovation-led contract research, development and manufacturing organization, from Biocon, an Indian biopharmaceutical company, for $153m.